Analyst Price Targets — CBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 8:52 pm | Stephen Willey | Stifel Nicolaus | $29.00 | $12.35 | StreetInsider | Crescent Biopharma Inc (CBIO) PT Lowered to $29 at Stifel |
| January 28, 2026 11:30 am | — | Piper Sandler | $35.00 | $11.27 | TheFly | Crescent Biopharma initiated with an Overweight at Piper Sandler |
| January 21, 2026 11:34 am | Brad Canino | Guggenheim | $35.00 | $13.98 | TheFly | Crescent Biopharma initiated with a Buy at Guggenheim |
| December 4, 2025 8:32 pm | Stephen Willey | Stifel Nicolaus | $32.00 | $12.99 | TheFly | Crescent Biopharma price target raised to $32 from $28 at Stifel |
| August 25, 2025 8:41 am | — | Jefferies | $26.00 | $14.70 | TheFly | Crescent Biopharma initiated with a Buy at Jefferies |
Latest News for CBIO
WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has closed its previously announced underwritten public offering of 9,387,896 ordinary shares, including 1,293,103 ordinary shares sold pursuant to the…
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up…
WALTHAM, Mass. , July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase…
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has commenced an underwritten public offering of its ordinary shares or, in lieu of ordinary shares to investors that so choose, pre-funded warrants to…
WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 65,100 shares of the Company's…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CBIO.
U.S. House Trading
No House trades found for CBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.